Advamedica Inc announces FDA clearance for Ax-Surgi Surgical Hemostat
Cambridge, Massachusetts: Advamedica Inc., a biomaterial focused medtech startup today announced the US Food and Drug Administration (FDA) 510(k) clearance for its latest innovation, Ax-Surgi Surgical Hemostat. With this, Ax-surgi has become first and only chitosan based hemostat cleared for controlling severe surgical bleeding.
Ax-Surgi is based on novel biopolymer platform and controls bleeding through its bioadhesive action. It is indicated for temporary control of internal organ space bleeding for patients displaying Class III or Class IV bleeding. It can also be used for control of severely bleeding wounds such as surgical wounds and traumatic injuries.
“We are very glad to receive this first of its kind clearance for a chitosan based hemostat for surgical indication which can help surgeons to control severe bleeding in many difficult surgeries and prevent blood loss” said Leo Mavely, President and CEO of Advamedica Inc. As the healthcare costs continue to rise, surgeons are looking for effective measures to reduce the duration of surgeries. These factors are propelling the demand for better and cost-effective solutions for controlling severe bleeding during the surgeries.
A number of products ranging from standard lap-sponges to absorbable hemostatic patches and sealants are available for the surgical bleeding control. Most of these are indicated to control minor bleeding and hence a major challenge for surgeons is to select a suitable hemostat that can be used in different grades of the bleedings. Many a times surgeons keep multiple products opened and ready for use to manage any emergency bleeding during the surgery. This strategy inadvertently leads to increased surgery costs due to wastage of resources.
Ax-surgi will fill this gap by offering a rapid acting hemostat for controlling moderate to severe bleeding from surgical and traumatic injuries. Ax-surgi is a ready to use, non-absorbable hemostat. It is composed of a 100% chitosan pad attached to a non-absorbable gauze backing with x-ray detectable grid which works through Advamedica’s proprietary protonated bioadhesive technology.
Visit http://www.ax-surgi.com/ for more info.
Founded in 2015 and based in Cambridge, MA (USA), Advamedica Inc. is a MedTech startup focused on advanced biomaterials for Hemostasis, surgical care and wound care. Company’s technologies are based on a proprietary platform of novel cationic biomaterials that exhibits charge based action to blood and mucosal tissues. Advamedica Inc. has raised over $20 million so far from investors such as Accel, University of California – Ratan Tata Fund, Omidyar Network, TrueScale capital and Chiratae Ventures. The company conducts advanced research in biomaterials in collaboration with Brigham and Women’s Hospital (BWH) at Harvard Medical School.
For more information on Advamedica and its solutions, visit www.advamedica.com